<DOC>
	<DOCNO>NCT00032305</DOCNO>
	<brief_summary>The purpose study evaluate intravenous ( injection ) investigational medication treat severe ulcerative colitis refractory steroid therapy . The research conduct 8 clinical research sit US open men woman age 18 70 year old . Participants study number visit research site . All study-related care medication provide qualified participant cost : include visit , examination laboratory work .</brief_summary>
	<brief_title>Research Study Patients With Severe Ulcerative Colitis</brief_title>
	<detailed_description>A Phase I , dose-escalation , pilot study design obtain safety tolerability data visilizumab administer patient severe ulcerative colitis fail respond steroid therapy . Patients currently receive IV corticosteroid , whose disease respond least 5 day therapy , eligible study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . A diagnosis ulcerative colitis verify colonoscopy barium enema perform within 36 month prior study entry . 2 . Active disease despite ongoing treatment steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Colitis</keyword>
	<keyword>Gastrointestinal Disease</keyword>
	<keyword>Digestive System Disease</keyword>
	<keyword>Intestinal Disease</keyword>
	<keyword>Colonic Disease</keyword>
</DOC>